Chek the Channels
Tuesday, April 21, 2020
PDS Biotechnology Corp (PDSB)
Expanding Product Pipeline into Infectious Diseases
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is primarily engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.
Cosme Ordonez, Senior Research Analyst, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
Versamune is a versatile platform technology. Versamune is a versatile platform technology. PDS Biotechnology, Corp. is developing a platform technology known as Versamune, which consists of lipid nanoparticles designed to deliver disease-specific antigens to stimulate a potent immune response. Versamune has potential applications for the treatment of cancer and infectious diseases. The Company's lead product PDS0101 is being developed for the treatment of HPV-associated cancers.
PDS is expanding its product pipeline. PDS has recently announced the commencement of programs to develop vaccines targeting COVID-19 and influenza. At present, the Company has three new programs in infectious diseases with one therapeutic vaccine PDS0201 against tuberculosis and two preventive vaccines, PDS0203/PDS0202, in development for COVID-19 and...
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.